Skip to content

Released Nov 6, 2023, before the open

10-Q filed Nov 6, 2023, 37 days after period end · 0001558370-23-017664

Q3 2023 · 10-Q
Revenue$10.35M−27.1% vs Q3 2022−70.5% vs Q2 2023
Net Income-$1.85MN/M vs Q3 2022N/M vs Q2 2023
EPS Diluted-$0.04N/M vs Q3 2022N/M vs Q2 2023
Operating Income-$1,887,000N/M
Operating Cash Flowderived-$6,888,000N/M
Free Cash Flowderived-$7,335,000N/M
Margins · derived
Operating margin-18.2%+3.8 pt vs Q3 2022
Net margin-17.9%+7.2 pt vs Q3 2022

What the release said

The release

Same quarter

MetricQ3 2023Q3 2022Q3 2021Q3 2020
Revenue$10.35M$14.18M$12.05M$10.79M
Net Income-$1.85M-$3.57M-$4.20M-$4.44M
EPS Diluted-$0.04-$0.07-$0.09-$0.14

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR